GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
14 juin 2021 07h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and...
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
11 juin 2021 03h00 HE
|
Global Blood Therapeutics, Inc.
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the...
GBT Announces New Employment Inducement Grants
04 juin 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2021, the compensation committee of GBT’s board of...
GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference
01 juin 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd...
GBT kündigt Präsentation von Daten auf dem virtuellen Kongress der European Hematology Association (EHA) 2021 an
12 mai 2021 10h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Kalifornien, May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) kündigte heute an, dass auf dem Virtuellen Kongress der European Hematology...
GBT présentera prochainement ses données à l’occasion du Congrès virtuel 2021 de l'Association européenne d'hématologie (EHA)
12 mai 2021 10h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Californie, 12 mai 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd'hui que six abstracts relatifs à son programme de...
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
12 mai 2021 10h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that six abstracts related to its sickle cell disease (SCD) programs...
GBT Announces New Employment Inducement Grants
07 mai 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2021, the compensation committee of GBT’s board of...
GBT Announces Participation in Upcoming Investor Conferences
06 mai 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following...
GBT Reports First Quarter 2021 Financial Results
05 mai 2021 16h05 HE
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe Advanced pipeline programs inclacumab and...